Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Xynomic Forms Partnership with UCSF for Cancer Drug Trial

publication date: May 23, 2017
Xynomic Pharma, a US-China oncology startup, entered a strategic partnership with the University of California San Francisco to conduct a Phase II/III clinical trial of its lead drug, abexinostat. Abexinostat is an HDAC inhibitor that is designed to overcome chemotherapy resistance, and Xynomic expects it will prove to be best-in-class. The company in-licensed global rights to abexinostat from AbbVie three months ago. Headquartered in Cheyenne, Wyoming, Xynomic also has operations in China. More details....

Stock Symbol: (NYSE: ABBV)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital